Adjuvant Chemotherapy for Breast Cancer in a Patient with Primary Autoimmune Neutropenia
نویسندگان
چکیده
We report an extremely rare and complex case of a 44-year-old woman diagnosed with an early stage triple negative breast cancer in the setting of primary autoimmune neutropenia with a pre-existing severe neutropenia. This case-report demonstrates that adjuvant chemotherapy for breast cancer can be administered in a patient with severe neutropenia. The management is however complicated and requires careful monitoring of side-effects related to both chemotherapy and treatment of autoimmune neutropenia. The role of chemotherapy in the treatment of triple negative breast cancer, the approach to autoimmune neutropenia and potential interactions are reviewed. To our knowledge, this is the first case reporting on the use of chemotherapy in a patient with severe pre-existing primary autoimmune neutropenia.
منابع مشابه
Main Determinants of Severe Neutropenia in Patients with Solid Tumors Receiving Adjuvant Chemotherapy
Background:Chemotherapy-induced neutropenia as a major toxicity of systemic chemotherapy is commonly associated with substantial mortality and morbidity, and thus identifying its determinants is necessary. This study was undertaken to identify main risk factors of severe neutropenia following adjuvant chemotherapy treatment in a community-based population of patients with cancer in Semnan, I...
متن کاملDoes adjuvant chemotherapy change bone mineral density and related serum biomarkers in women with breast cancer?
Background: The primary objective of this study was to assess BMD change in Iranian females with breast cancer. Methods: A sample of 73 female breast cancer patients treated with adjuvant chemotherapy either alone or followed by radiotherapy between March 2013 and February 2016 were considered for this study. Bone mineral density (BMD) change was evaluated by measuring z-score of lumbar spin...
متن کاملDocetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Optimal management of locally advanced breast cancer (stage III) generally includes a combination of primary chemotherapy followed by surgery (if feasible), and local radiotherapy and adjuvant chemotherapy with or without hormonal therapy. An ongoing phase II study is being performed to evaluate the use of 4 cycles of 100 mg/m2 of docetaxel (Taxotere) administered as a 1-hour intravenous infusi...
متن کاملLife-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer.
CONTEXT Adjuvant chemotherapy with new cytotoxic agents for breast cancer must be properly assessed for toxicity. OBJECTIVE To describe adverse events associated with adjuvant chemotherapy for breast cancer, which led to premature termination of a clinical trial. DESIGN, SETTING, AND PATIENTS We conducted a prospective randomized multicenter study (Reposant sur des Arguments Pronostiques et...
متن کاملUse of G-CSF to Sustain Dose Intensity in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Pilot Study.
BACKGROUND: Adjuvant chemotherapy for breast cancer is frequently accompanied by neutropenia requiring dose reduction or treatment delay that can potentially compromise therapeutic effectiveness. Recombinant granulocyte-colony stimulating factor (G-CSF) reduces the duration and severity of neutropenia. METHODS: Nineteen patients with newly diagnosed breast cancer receiving adjuvant systemic che...
متن کامل